Developing biomarkers for personalized radiotherapy in lung cancer
Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
University of Manchester · NCT06086574
This study is trying to find specific markers in patients with stage 3 lung cancer to help doctors personalize their treatment and improve their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Manchester (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Manchester) |
| Trial ID | NCT06086574 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with stage 3 non-small cell lung cancer (NSCLC) to identify biomarkers that can personalize treatment approaches. It aims to utilize circulating tumor DNA and information from medical imaging and patient-reported outcomes to predict treatment responses and outcomes. By tailoring therapies based on these biomarkers, the study seeks to address the unmet clinical need for more effective treatment strategies in this patient population. The goal is to improve patient management and potentially enhance survival rates.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed stage 3 NSCLC who are unsuitable for surgery and are planned to receive radical radiotherapy or chemoradiotherapy.
Not a fit: Patients with mixed non-small cell and small cell tumors or those who have undergone adjuvant radiotherapy post-surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with stage 3 lung cancer.
How similar studies have performed: Other studies have shown success in using biomarkers for personalized treatment in metastatic lung cancer, indicating a promising direction for this approach in stage 3 NSCLC.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Histological or cytologically confirmed NSCLC. * Unsuitable for surgery due to tumour or patient factors. * Stage 3 A, B or C (TNM version 8). * Planned to receive radical radiotherapy OR sequential chemoradiotherapy OR concurrent chemoradiotherapy +/- consolidation immunotherapy. * Predicted life expectancy \>12 weeks. * Ability to provide written informed consent. * Willingness to comply with study procedures. Exclusion criteria: * Mixed non-small cell and small cell tumours. * Adjuvant radiotherapy post-surgery. * Participation in a study of an interventional study as part of lung cancer treatment. * Recent/active malignant disease which might impact study results. * Psychotic disorders/cognitive impairment.
Where this trial is running
Manchester
- The Christie NHS Foundation Trust — Manchester, United Kingdom (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer Stage III, Non small cell lung cancer, NSCLC, Stage III, Radiotherapy, Biomarker, Circulating-tumour DNA, Radiomics